<DOC>
	<DOCNO>NCT02902900</DOCNO>
	<brief_summary>This study , national , multicenter , observational , ambispective , non-interventional study , conduct French hospital prescribe pomalidomide already participate ongoing Imnovid registry . This study add registry . Indeed , pomalidomide-prescribing physician pharmacist dispense pomalidomide enter Imnovid registry patient prescribe drug since date market regardless initiation date pomalidomide indication prescribe .</brief_summary>
	<brief_title>An Efficacy Study Pomalidomide Patient With Multiple Myeloma Routine Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Adult patient ( age â‰¥ 18 yr ) , Diagnosed multiple myeloma ( measurable ) , In pomalidomide treatment first initiate October 1 , 2014 , September 30 , 2017 , Patient already include Imnovid registry , Having receive oral write information study , give consent participate . Previous participation clinical trial pomalidomide , Treatment pomalidomide previous line , Simultaneous participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>Efficacy</keyword>
</DOC>